Neuronal Nicotinic Receptors - August 2008
Subscribe now and receive the next 12 monthly issues of UpdatesPlus for £5000
Neuronal nicotinic receptor ligands are fast proceeding through clinical development as exciting candidates for multiple CNS disorders including Alzheimer's disease; Schizophrenia; ADHD; Depression; Pain and Addiction.
Are you involved in these areas; are you developing nicotinic receptor ligands? If so UpdatesPlus is for you. This service, brought to you from the pharmaceutical analysts, LeadDiscovery, not only delivers all key breaking research, drug development news and clinical trials in this area, it also analyzes it.
Published monthly along with a fully up to date pipeline of nicotinic receptor therapeutics, UpdatesPlus offers a key insight into the strategy and development within the nicotinics arena. Offering an ideal intelligence tool for everyone from brand managers to medical directors and preclinical managers, UpdatesPlus is a must for all involved in this exciting new field of medicine
See December 2007 edition now (free sample copy)
Table of Contents
What's in the August 2008 edition of UpdatesPlus-Nicotinic Receptors?
- A progress report on Memory Pharmaceuticals' nicotinics program: LeadDiscovery provides update on MEM 3454/R3487 including information on the biomarker study planned for this candidate in schizophrenia patients.
- Information on new nicotinic agonists emerging from the Siena Biotech/Wyeth collaboration: UpdatesPlus provides up to date information on the collaboration between these two companies aimed at developing new treatments of Alzheimer’s disease. Particular attention is paid to a new and recently disclosed series of molecules
- AstraZeneca's development of new α7 agonists: News is provided on a recent patent published by AstraZeneca claiming a new series of agonists
- Information on Pfizer's continued reaction to the downturn in Champix/Chantix sales plus GSK's attempts to maintain pressure on Pfizer: LeadDiscovery provides analysis of Pfizer’s strategy to reverse the downward trend in Chantix sales figures. Pfizer is focussing on new marketing initiatives as well as the development of new formulations of varenicline. In particular, information is offered on the advancement of a varenicline gum. As Pfizer attempts to drive Champix/Chantix forwards, GSK is trying to maintain a negative focus on the franchise. UpdatesPlus discusses these efforts.
- A progress report from Targacept plus information on a potential new development program underway at the company: UpdatesPlus presents a summary of Targacept’s Q2 conference call and also evaluates new technology which could result in the development of a treatment of breakthrough pain or migraine based on a nicotinic nasal spray
- Information on promising candidates for smoking cessation and for the prevention of lung cancer being developed by HBRI: LeadDiscovery had identified what it believes to be a highly promising licensing opportunity being developed by HBRI. This technology has the potential to both reduce nicotine addiction and protect against the harmful effects of smoking
- Full and up to date pipeline
Pricing & Delivery: UpdatesPlus is available on a subscription basis. A one-off payment will get you the next twelve monthly editions of UpdatesPlus-Nicotinic Receptors plus access to all past editions. UpdatesPlus is available for unlimited use within your company. Delivered in a powerpoint format, UpdatesPlus is both easy to use and also ready for use within a presentation setting
2008 issues:
About UpdatesPlus: Through DailyUpdates, LeadDiscovery has access to one of the most comprehensive sources of information for the drug development sector. UpdatesPlus takes this information and uses our industrial experience to provide a monthly analysis of breaking activity in selected indications and molecular targets. If this is the first time that you have heard of UpdatesPlus please take a moment to have a look at an example. If you would find such a service of use in your area contact us now.
Other users found this report page using the following search terms: Neuronal Nicotinic Receptors - July 2008 neuronal Nicotinic Receptors nicotinic receptors cognition cognitive cias alzheimer amyloid depression adhd smoking cessation alpha7 alpha6 alpha4beta2 nicotinic adhd alzheimers nicotine memory LeadDiscovery Pharmaceutical reports Market Research market research reports pharmaceutical business reports Pharmaceutical Market Research Reports reports pharmaceutical research pipeline nicotinic nicotinics monthly nicotine receptors neuronal 2008 alzheimers receptor schizophrenia
If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.
Refund and Cancellation Policy: The descriptions of the products and services sold on LeadDiscovery.co.uk are as complete and accurate as possible, and customers are encouraged to read all available information about a product before placing an order. Due to the nature of the information being sold, orders for reports cannot be canceled.